Technologies

4basebio has proprietary technology in the fields of DNA synthesis and payload delivery which enables us to manufacture both synthetic DNA constructs and mRNA and develop vectors for cell and tissue specific delivery for a range of applications.

Our expertise also extends to the development of AAV vectors for early stage pre-clinical research.

See how we can support your gene therapy or vaccines programme

Ovewview

4basebio has developed synthetic DNA template technology which is manufactured enzymatically and consequently is non-bacterial. In comparison to plasmid DNA, this is safer, more readily available, more flexible, and more efficient for use in applications such as AAV and Lentivirus viral production for gene and cell therapies, mRNA vaccines and therapeutics, genome editing, DNA vaccines and non-viral gene and cell therapies.

The principal features of these DNA products are as follows:

  • hpDNA™ is a double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends and ideally suited for viral and non-viral vector applications.
  • osDNA™ incorporates nucleotide modifications within the DNA backbone providing resistance to exonuclease degradation, as well as tuning of the immunostimulatory properties of the construct, making osDNA™ ideally suited for DNA vaccine applications.
  • opDNA™ is a partially opened, linear, double stranded DNA product. Each opDNA™ molecule features a hairpin on either the 3’ or 5’ end, with an opposite open end. The open end of the construct can include an overhang or blunt end. This product is ideally suited as a template for IVT production of mRNA.
  • oeDNA™ is a linear open-ended, double stranded DNA product where both 3’ and 5’ ends are open. Constructs can be generated with blunt ends, overhangs or any combination thereof. This format is ideal for both IVT production of mRNA, and genome editing by homology directed repair (HDR).

All formats offer the following benefits:

Speed & scale:

  • Fast manufacturing and downstream process
  • Scalable process from µg to multigram batches
  • No master cell bank or yield optimisation needed
  • Suitable for rapid multi construct screening
  • Suitable for barcoding
  • No risk of batch failure

Safety and compliance:

  • No bacterial sequences
  • No antibiotic resistance genes
  • No bacterial contaminants (endotoxins, host protein, genomic DNA…)

Flexibility & efficiency:

  • Suitable for complex sequences (ITRs, long continuous poly-A tails…)
  • Suitable for long sequences (such as 12kb)
  • Suitable for sequences toxic to bacteria
  • More genome copies per gram

Reproducibility:

  • Sequence and size independent
  • Defined, controlled and scalable process
  • Simple and consistent downstream purification process
  • High Fidelity

Hermes™ is a targeted non-viral delivery platform. Nanoparticle vectors are engineered to target specific cells or tissues of interest, combining the benefits of nanoparticles with the specificity of a targeting system:

Safety:

  • Non-viral nanoparticles
  • Low immunogenicity, suitable for repeat dosing
  • Targeting mitigates off-target effects

Specificity:

  • Delivery to specific cells or tissues through built-in targeting system
  • Uptake via endocytosis and efficient endosomal escape

Flexibility:

  • Suitable for large transgenes
  • Suitable for different payloads (DNA, RNA, protein, or combinations thereof)
  • Suitable for various ROAs including IV

Efficiency:

  • Controlled and cost-effective manufacturing process
  • Self-assembly and no conjugation